GlassScriptPhysician profile
Danielle G Raley
NPI 1194169466
$11,535.89
in general payments reported to CMS, 2019-2025
49 companies · $1,448 in 2025
The $1,448 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,452 · 2020: $1,510 · 2021: $2,118 · 2022: $2,026 · 2023: $1,741 · 2024: $1,242 · 2025: $1,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,385 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,385.39 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,079.15 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,208.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $864.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $832.95 | 2019-2025 | Repatha, Evenity, Otezla |
| Astrazeneca Pharmaceuticals LP | $678.47 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $564.40 | 2020-2024 | Trintellix |
| Merck Sharp & Dohme LLC | $554.05 | 2019-2025 | Steglatro, Belsomra, Capvaxive |
| Pfizer INC. | $485.05 | 2019-2025 | |
| Abiomed | $387.24 | 2022-2024 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $383.14 | 2022-2025 | |
| Abbott Laboratories | $350.08 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $337.34 | 2019-2022 | |
| Allergan, INC. | $301.31 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.26 | 2019-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.58 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Raley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.